Biopharma Daily Stock Updates - 09/23/21

$XBI $133.07 +1.88%

---

Pipeline Updates

$VTVT +19.2% vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis source

$PRTK +8.4% Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2021 source

$GLYC +3.2% Efficacy and Safety Data for GlycoMimetics’ Lead Investigational Drug Uproleselan Published in BLOOD source

$SRRK +7.4% Scholar Rock Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress source

$JAGX +6.6% Jaguar Health Receives "Complete" Letter from FDA for Last of Four Major Technical Sections for the Company's Application for Conditional Approval of Canalevia (Crofelemer) for Chemotherapy-Induced Diarrhea (CID) in Dogs source

$HZNP -0.4% Horizon Therapeutics plc Announces Data Showing UPLIZNA® (inebilizumab-cdon) Also Produces Rapid and Sustained B-Cell Depletion in African Americans with Neuromyelitis Optica Spectrum Disorder (NMOSD) source

$AYLA -2.8% Ayala Pharmaceuticals Announces Publication Highlighting Clinical Activity of its Gamma Secretase Inhibitor AL101 in Desmoid Tumors source

$SCYX -1.6% SCYNEXIS to Present Data on Oral Ibrexafungerp at IDWeek 2021 from Interim Analyses of Phase 3 FURI Clinical Trial Showing Therapeutic Response Rates in Patients with Mucocutaneous and Invasive Fungal Infections source

$CLDX +3.1% Celldex Announces Upcoming Presentation of CDX-0159 Phase 1b Results in Inducible Urticaria at the 2021 European Academy of Dermatology and Venereology (EADV) 30th Congress source

$TFFP +0.3% TFF Pharmaceuticals Announces Promising Topline Results from Phase 1 Clinical Trial of Inhaled Tacrolimus Powder and Progression Toward Phase 2 in Lung Transplantation source

$TGTX +3.9% TG Therapeutics Announces Publication of Results from an Integrated Safety Analysis of UKONIQ® (umbralisib) in Blood Advances source

$NOVN +0.7% Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206 source

$IOVA +2.6% Iovance Biotherapeutics Initiates Clinical Supply of Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy Manufactured at Iovance Cell Therapy Center (iCTC) source

$RNAZ +53.4% TransCode Therapeutics Announces Publication in Cancer Nanotechnology of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Metastatic Breast Cancer source

$PSTV +-0.0% PLUS THERAPEUTICS TO PRESENT RHENIUM-186 NANOLIPOSOME DATA AT THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY (ASTRO) 2021 ANNUAL MEETING source

$BLU +5.0% BELLUS Health Announces Completion of Patient Enrollment in SOOTHE Phase 2b Trial for Refractory Chronic Cough and BLUEPRINT Phase 2a Trial for Chronic Pruritus Associated with Atopic Dermatitis source

$IMCR -0.4% Immunocore announces publication of phase 3 data comparing tebentafusp with investigator’s choice in The New England Journal of Medicine source

$CLNN -1.4% Clene Announces Initiation of a Second FDA Expanded Access Program with CNM-Au8 for People Living with Amyotrophic Lateral Sclerosis source

$BEAM +2.8% Beam Therapeutics Announces Updated Preclinical Data Highlighting Optimized LNP Delivery Approaches for In Vivo Base Editing to the Liver and Other Tissues source

$VERV +10.6% Verve Therapeutics Reports New Preclinical Data with VERVE-101 Demonstrating Robust, Durable and Precise Editing of the PCSK9 Gene for the Treatment of Cardiovascular Disease source

$SLDB -1.3% Solid Biosciences Reports 1.5-Year Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001 source

Finance & Business Updates

$ONTX -18.9% Onconova Therapeutics, Inc. Announces Proposed Public Offering Of Common Stock source

$RDHL +4.0% RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Aurobindo source

---

Posted by JM